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Expression of endothelial and inducible nitric oxide synthase in human
glomerulonephritis. The presence of nitric oxide (NO) in the kidney has
been implicated in the pathogenesis of human glomerulonephritis. How-
ever, the exact type of glomerular cells that express NO synthase (NOS)
and the NOS isoform involved in the local production of NO has not been
identified in the human diseased kidney. We examined the expression of
three isoforms of NOS, inducible NOS (iNOS), endothelial NOS (eNOS)
and brain NOS (bNOS) in the renal tissue of patients with IgA nephrop-
athy (IgAN, N 5 10), lupus nephritis (LN, N 5 5), membranous
nephropathy (MN, N 5 5) and minimal change nephrotic syndrome
(MCNS, N 5 5). Sections were immunostained and the correlation
between the expression of each NOS and the degree of glomerular injury
in that section was also examined. Normal portions of surgically resected
kidneys served as controls. eNOS was present in glomerular endothelial
cells and endothelium of cortical vessels in the control and diseased
kidneys. iNOS was localized in mesangial cells, glomerular epithelial cells
and infiltrating cells in the diseased glomeruli, whereas immunostaining
for iNOS was hardly detected in control kidneys. In addition, the
expression pattern of eNOS in each glomerulus was the reverse of that of
iNOS. In IgAN and LN, the extent of staining for eNOS correlated
negatively with the degree of glomerular injury, while the extent of
staining for iNOS correlated positively with the degree of glomerular
injury in the same tissues. bNOS was not detected in normal or nephritic
glomeruli. Our results indicate the presence of a NO pathway in human
diseased kidney, and suggest that NO derived from eNOS and iNOS may
be involved in the progression of renal diseases and that NO derived from
each NOS may play an important role in different way in human inflamed
glomeruli.
Nitric oxide (NO) has broad biological properties as an inter-
cellular messenger molecule acting as a vasodilator and neuro-
transmitter, and is also involved in inflammation, tissue injury and
cell defense [1, 2]. The synthesis of NO is catalyzed by nitric oxide
synthase (NOS) [1] and three isoforms of NOS, endothelial NOS
(eNOS), brain NOS (bNOS) and inducible NOS (iNOS), have
been identified [3, 4]. The constitutive forms of NOS, such as
bNOS and eNOS, are present in endothelial cells and neurons,
while iNOS is present in different types of cells, including
macrophages, vascular endothelial cells, vascular smooth muscle
cells, epithelial cells, neutrophils and fibroblasts [1]. eNOS and
bNOS generate small quantities of NO, which is important in
signal transduction including the regulation of vascular tone [2, 5],
whereas iNOS, which can be induced by cytokines and endotoxin,
produce large quantities of NO with cytotoxic/cytostatic effects [2, 6].
With regard to the role of NO in the kidney, previous reviews
[2, 7] showed that in the physiological state, NO is mainly derived
from constitutive NOS, such as eNOS and bNOS, and that NO
contributes to the regulation of the glomerular microcirculation
and the inhibition of platelet aggregation and adhesion. In
contrast, in pathological conditions NO is generated by isolated
nephritic glomeruli, as shown in four different rat models of
immune complex-mediated glomerulonephritis [8–11]. However,
the role of NO in renal diseases is still controversial. Inhibition of
NO production in vivo in experimental glomerulonephritis pro-
duces inconsistent results. For example, in anti-Thy-1 model and
MRL-lpr/lpr mice, inhibition of NO production by administration
of the NOS inhibitor NG monomethyl-L-arginine reduced glo-
merular injury [12], while the same treatment worsened the
degree of proteinuria in nephrotoxic nephritis [13].
Several studies have examined the constitutive NOS expression
in kidney [14–16]. Lamas et al [14] showed that eNOS mRNA is
synthesized by cultured glomerular endothelial cells. More re-
cently, Goto et al [15] showed that glomerular expression of eNOS
mRNA in anti-Thy-1 glomerulonephritis increased biphasically
and that bNOS mRNA was not detected in the same model;
however, the localization of eNOS mRNA was not determined in
that study. In normal human kidney, using immunohistochemistry
and in situ hybridization, Bachmann, Bosse and Mundel [16]
identified the expression of eNOS in glomerular endothelial cells
and afferent/efferent arterioles, while bNOS was expressed in the
efferent arterioles, macula densa and Bowman’s capsule. How-
ever, the expression of eNOS and bNOS has not been reported in
human diseased kidney.
With regard to iNOS expression, Mohaupt et al [17] reported
that iNOS mRNA was produced by cultured mesangial cells
stimulated by tumor necrosis factor-a (TNF-a) and interferon-g
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(IFN-g), and that microdissected glomeruli of normal and lipopo-
lysaccaride-treated rats also synthesized the mRNA. Although it
was suggested that iNOS is synthesized in mesangial cells in vivo,
two experimental models of glomerulonephritis showed that
infiltrating leukocytes, not mesangial cells, expressed iNOS [15,
18]. Using immunohistochemistry, Jansen et al [18] showed that
the majority of iNOS expressing cells in glomeruli of rats with
immune complex glomerulonephritis were macrophages. In con-
trast, in an anti-Thy1 model, most of the cells positive for iNOS in
the glomeruli possessed a marker for polymorphonuclear leuko-
cytes [15].
These findings suggest the involvement of NO in the develop-
ment and progression of human glomerulonephritis. However,
whether glomerular resident cells express the NOS isoform or
which isoform of NOS is involved in the local production of NO
have not been clarified in human diseased kidney. In the present
study, we examined the expression of the above three NOS
isoforms in biopsy specimens obtained from patients with various
forms of glomerulonephritis using immunohistochemistry, and
also analyzed the correlation between the expression of each NOS
and the degree of glomerular injury.
METHODS
Kidney tissues
We examined a total of 25 renal biopsy specimens from 25
patients with renal diseases, including 15 patients with prolifera-
tive [10 IgA nephropathy (IgAN) and 5 lupus nephritis-type IV
(LN)] and 10 nonproliferative [5 membranous nephropathy (MN)
and 5 minimal change nephrotic syndrome (MCNS)] glomerulo-
nephritis. Five tissue specimens from uninvolved areas of adeno-
carcinomatous kidneys served as normal controls. All patients
gave informed consent to renal biopsy and the present study. The
diagnosis was established based on clinical, immunofluorescence,
light and electron microscopic findings. The clinical data are
summarized in Table 1. The following laboratory parameters were
determined: proteinuria, hematuria and serum creatinine. The
severity of hematuria was graded as: grade 0, representing 0 to 5
erythrocytes per high-power field; grade 1, 5 to 30 erythrocytes per
high-power field; grade 2, .30 erythrocytes per high-power field;
and grade 3, representing macroscopic hematuria. All patients
were normotensive and none received steroids or immunosup-
pressive drugs prior to renal biopsy. Immunofluorescence, light
and electron microscopic examination were performed routinely
to establish the histological diagnosis. For immunohistochemistry,
a portion of the cortical fragment was embedded in O.C.T.
compound (Miles Inc., Elkhart, IN, USA) and quickly frozen in
ethanol bath with dry ice and stored 280°C until use.
Immunohistochemistry
Indirect immunoperoxidase staining was performed using
monoclonal antibody against eNOS, iNOS and bNOS (N30020,
N32020 and N31020, respectively) purchased from Transduction
Laboratories (Lexington, KY, USA). A monoclonal antibody
against CD68 (M718; Dako, Glostrup, Denmark) was also used to
identify any infiltrating monocytes. Using the avidin biotin com-
plex method with kits from Vector Laboratories (PK-6102; Bur-
lingame, CA, USA), staining for NOS and CD68 was performed
as previously described [19]. Briefly, cryostat sections (4 mm) were
fixed with 4% paraformaldehyde in phosphate buffered saline
(PBS) and washed in PBS. The sections were incubated for 30
minutes with 3% H2O2 to eliminate endogenous peroxidase
activity. After rinsing in PBS, the sections were treated with
blocking serum and incubated with the primary antibody. In the
next step, the sections were washed with PBS and incubated with
the biotinylated secondary antibodies. After washing, the sections
were incubated for 30 minutes with the Vectastain ABC reagent.
Color was developed by reacting with 3,39-diaminobenzidine/
tetrahydrochloride and H2O2.
To determine the contribution of macrophages to the popula-
tion of cells positive for iNOS in glomeruli, double immunolabel-
ing for iNOS and CD68, a surface marker of macrophages, was
performed according to the methods of Berkes et al [20]. After
staining iNOS using the protocol described above, the tissue
sections were washed in PBS and then treated with blocking
serum and incubated with anti-CD68 antibody for 60 minutes at
room temperature. Biotinylated secondary antibody and Vec-
tastain ABC reagent applied sequentially as mentioned above,
and second chemogen, TrueBlue Substrate (71-00-64; KPL,
Gaithersburg, MD, USA) was applied, resulting in the staining of
positive cells in blue color.
Histological examination and evaluation of the expression of
NOS isoforms in each biopsy were performed by two observers
independently without prior knowledge of the clinical and labo-
ratory data. For semiquantitative histological grading of the
glomeruli, after the color development of immunohistochemistry,
the sections were stained by periodic acid-Schiff reaction (PAS),
which allowed the identification of histological changes such as
mesangial expansion and the exact location of those cells positive
for NOS isoforms relative to the glomerular basement membrane
and mesangial area. Since the degree of glomerular injury is
heterogeneous among glomeruli during the progression of glo-
merulonephritis [21], it is possible that the level of expression of
NOS isoforms may relate to the degree of injury in each glomer-
ulus. Hence, we evaluated the degree of glomerular injury as well
as expression of each NOS isoform in each glomerulus rather than
averaging the injury in each section. Five to seven glomeruli, each
with an equatorial plane cross-section, were analyzed per biopsy.
The glomerular changes were graded into four classes ranging
from 0 to 31 (minimal, mild, moderate and severe) according to
the proportion of the involved region in the sectioned areas of
each glomerulus, based on the method described by Okada et al
[22] with a minor modification. Grade 0 represented injury
involving of less than 10% of the glomerulus, grade 1 between
10% and 30%, grade 2 between 30 and 60% and grade 3
represented involvement exceeding 60%.
After determining the degree of glomerular injury, in the same
Table 1. Clinical data of patients participating in the study
Case N
Age
years
Proteinuria
g/day
Hematuria
index
Serum
creatinine
mg/dl
IgAN 10 38 6 10 1.0 6 0.9 1.7 6 1.2 1.1 6 0.3
LN 5 30 6 10 2.5 6 1.3 2.0 6 1.1 1.1 6 0.3
MCNS 5 23 6 6 7.2 6 6.5 0.4 6 1.0 0.8 6 0.4
MN 5 45 6 17 1.7 6 1.0 0.7 6 0.7 0.8 6 0.1
Data are mean 6 SD. Abbreviations are: IgAN, IgA nephropathy; LN,
lupus nephritis-type IV; MCNS, minimal change nephrotic syndrome;
MN, membranous nephropathy.
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Fig. 1. Immunohistochemistry for endothelial nitric oxide synthase (eNOS) in normal kidney (A) and in renal sections of patients with IgA
nephropathy (IgAN; B-D), lupus nephritis (LN, E-F), minimal change nephrotic syndrome (MCNS; G), and membranous nephropathy (MN; H). To
identify the precise localization of eNOS positive cells in the glomeruli, the renal sections are counterstained by PAS (3200). (A) In normal kidney,
a number of glomerular endothelial cells are positively stained for eNOS (arrows). (B) Endothelial expression of eNOS in the glomerulus (arrows) and
in peritubular capillaries (arrowheads) in renal tissue of IgAN with mild lesion. (C) Note absence of positive cells for eNOS in the area of mesangial
expansion (the area surrounded by arrows) in glomeruli of a representative patient with IgAN. In contrast, staining for eNOS is still observed in mildly
injured area (the area surrounded by arrowheads). (D) eNOS is hardly detected in the sclerotic glomeruli of patient with IgAN. (E) In the renal tissue
of LN with moderate lesion, glomerular endothelial cells in the area of mesangial expansion are not stained for eNOS, whereas in mildly injured areas,
cells positive for eNOS are observed. (F) Only a few cells positive for eNOS are observed in severely injured glomeruli of patients with LN. (G and H)
The expression patterns of eNOS in the renal tissue of MCNS (G) and MN (H) are similar to that in control (A).
Furusu et al: Expression of eNOS and iNOS in human GN1762
glomeruli, semiquantitation of the expression of each NOS iso-
form in kidney tissues from patients with various types of glomer-
ulonephritis was performed according to the methods of Roy-
Chaudhury et al [23]. Briefly, a scoring scale from 0 to 3 was used
as follows: 0 5 no specific staining, 0.5 5 possibly positive, 11 5
weakly positive, 21 5 moderately positive, 31 5 strongly posi-
tive. Scoring was generally influenced by the extent rather than the
intensity of staining.
Specificity of anti-inducible nitric oxide synthase antibody
To determine the specificity of anti-iNOS antibody, various
control studies were performed. First, an absorption test using
mouse iNOS (60862; Cayman Chemical Company, Ann Arbor,
MI, USA) was performed. Briefly, 125 ml of PBS containing 40
mg/ml of monoclonal antibody was incubated with 125 ml of PBS
containing 0 mg, 5 mg, 10 mg of mouse iNOS for one hour at 4°C
and processed for indirect immunohistochemistry as described
above. Second, irrelevant monoclonal antibodies with the same
IgG subclass of the first antibodies, nonspecific mouse IgG1
(Dako X931) and IgG2 (Dako X0943), were used instead of the
specific antibody for negative controls in immunohitstochemistry.
Third, omission of primary antibody in the peroxidase system
served as additional control. Finally, the specificity of immuno-
staining for iNOS was also verified in a few samples using a
different anti-iNOS antibody, a rabbit polyclonal antibody to
iNOS (SA-200; BIOMOL, Plymouth Meeting, PA, USA).
Furthermore, in order to demonstrate synthesis of iNOS by
glomerular cells, in situ hybridization for iNOS was performed
using some renal sections and 25-mer digoxigenin-labeled oligo-
nucleotide, which corresponded to the base number 3525-3549 of
human iNOS cDNA [24], as described elsewhere [18]. The
selected sequences showed no significant similarity with known
sequences deposited in the gene data bank (GenBank Rel. 85,
December 1996). In brief, a fresh frozen renal tissue, fixed with
4% paraformaldehyde, was deproteinized using HCl and protein-
ase K. After hybridization with the probe, immunohistochemistry
was performed to visualize DIG-labeled probe using mouse
monoclonal anti-DIG antibody (Boehringer 1333 062), followed
Fig. 2. Immunohistochemistry for inducible nitric oxide synthase (iNOS)
in normal and in renal sections of patients with IgA nephropathy (IgAN),
lupus nephritis (LN) and membranous nephropathy (MN). (A) Note the
lack of positive immunostaining for iNOS in the control kidney. Only
nuclei are stained by methylgreen in cells negative cells for iNOS (3200).
(B) Cells positive for iNOS are observed in the glomeruli of IgAN with a
mild lesion (arrows). (C) The number of glomerular cells positive for
iNOS was higher in glomeruli of IgAN with moderate lesion. The signal
was located in mesangial area (arrowheads; 3200). (D) A few cells
positive for iNOS are observed in mildly injured glomeruli of patients with
LN (arrows; 3200). (E and F) Note the remarkable expression of iNOS in
the glomeruli with severe lesion in LN. Immunoreactive iNOS is localized
in glomerular epithelial cells (arrowheads) and mesangial area (arrows).
(G) Positive immunostaining for iNOS is hardly detected in glomeruli of
MN (3200). (H) Control for the specificity of anti-NOS antibody.
Irrelevant antibody of the same subclass, non-specific mouse IgG2 in place
of the primary antibody, used as a negative control, yields no staining.
Fig. 3. In situ hybridization for inducible nitric oxide synthase (iNOS)
mRNA, followed by PAS staining, in renal sections of patients with IgAN
(3200). Cells positive for iNOS mRNA were detected in glomeruli
(arrowheads).
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by horseradish peroxidase-conjugated antibodies. Color was de-
veloped by reacting with H2O2 and 3,39-diaminobenzidine/tetra-
hydrochloride. To evaluate the specificity of the technique, vari-
ous control experiments including pre-treatment of RNase, a
study with a sense probe and a competitive study were performed
as described previously [25, 26].
Statistical analysis
Data were expressed as mean 6 SD. Differences between different
groups were tested for statistical significance using one-way analysis
of variance (ANOVA) with Scheffe’s F test. Correlation between
the degree of glomerular injury and expression of each NOS
isoforms per glomerular cross-section was analyzed using the
Spearman’s rank correlation test as described previously [27].
RESULTS
The results of staining by immunohistochemistry for eNOS are
shown in Figure 1 and summarized in Table 2. In the control
tissue, eNOS was present in glomerular endothelial cells (Fig.
1A), endothelial cells of afferent and efferent arterioles, and
cortical vessels. The expression pattern of eNOS in the renal
tissue of IgAN with mild lesion (Fig. 1B), MCNS (Fig. 1G) and
MN (Fig. 1H) was similar to the control (Fig. 1A). The degree of
the expression of eNOS in IgAN with minimal to mild lesion, LN
with minimal to mild lesion, MCNS and MN was higher than
control (Table 2; P 5 0.157, , 0.01, , 0.01, 5 0.142, respectively).
In contrast, in glomeruli with moderate lesion in IgAN (Fig. 1C)
and LN (Fig. 1E), eNOS expression was low in glomerular
endothelial cells within the area of mesangial expansion, while
staining of eNOS was still observed in areas with mild injury. In
the sclerotic glomeruli of patients with IgAN and LN, eNOS was
hardly detected (Fig. 1 D, F). In IgAN and LN, the extent of
staining for eNOS correlated significantly and negatively with the
degree of glomerular injury (Table 3).
The results of immunohistochemical staining for iNOS are
shown in Figure 2 and Table 2. While iNOS expression was hardly
detected in glomeruli of MCNS, MN (Fig. 2G) and control tissue
(Fig. 2A), cells positive for iNOS were clearly detected in the
glomeruli of IgAN (Fig. 2 B, C) and LN (Fig. 2 D-F). In IgAN and
LN, iNOS was localized in the mesangial area (Fig. 2 C, E, F) and
glomerular epithelial cells (Fig. 2 E, F). We also demonstrated the
synthesis of iNOS mRNA in glomerular cells using in situ hybrid-
ization. As shown in Figure 3, iNOS mRNA signals were detected
in glomeruli of IgAN and LN. The degree of iNOS expression in
the glomeruli of IgAN and LN was significantly higher than that
in MCNS, MN and control kidney (Table 2). In IgAN and LN, the
extent of staining for iNOS correlated positively with the degree
of glomerular injury (Table 3).
The results of immunostaining for iNOS and CD68 in the serial
sections are shown in Figure 4 A and B. Although monocytes were
occasionally observed in the glomeruli, the staining pattern for
Table 2. Glomerular expression of eNOS and iNOS in normal and
diseased kidney
Diagnosis
eNOS score/
glomerulusb
iNOS score/
glomerulusb
IgAN
minimal-mild lesiona 1.59 6 0.44 0.96 6 0.39c
moderate-severe lesiona 0.42 6 0.33 1.23 6 0.57c
LN
minimal-mild lesiona 2.24 6 0.56c 0.90 6 0.62c
moderate-severe lesiona 0.47 6 0.33 1.56 6 0.73c
MCNS 1.81 6 0.61c 0.10 6 0.20
MN 1.57 6 0.50 0.08 6 0.18
Control kidney 1.13 6 0.34 0.07 6 0.18
Data are means 6 SD.
a The glomerular injury was graded from 0 to 31 according to the
proportion of involved regions in sectioned surface areas of each glomer-
ulus according to the method described by Okada et al [22] with a minor
modification. Grade 0 represented involvement of less than 10%, grade 1
between 10% and 30%, grade 2 between 30 and 60% and grade 3
represented involvement exceeding 60%.
b In each glomerulus, the degree of eNOS and iNOS staining were
scored according to the methods of Roy-Chaudhury et al [23]. Five to
seven glomeruli in each section were analyzed. Differences between
groups were tested for statistical significance using one-way analysis of
variance (ANOVA) with Scheffe’s F test.
c P , 0.01 versus Control kidney
Table 3. Correlation between eNOS and iNOS expression and degree
of glomerular injury in IgAN and LN patients
Glomerular injuryb
IgAN LN
eNOS expressiona 20.626c 20.706c
iNOS expressiona 0.230d 0.487c
a In each glomerulus, the degree of eNOS and iNOS staining was scored
according to the methods of Roy-Chaudhury et al [23]. Five to seven
glomeruli in each section were analyzed. Cells containing clearly stained
cytoplasm were identified as eNOS and iNOS positive cells.
b The glomerular injury was graded from 0 to 31 according to the
proportion of involved regions in sectioned surface areas of each glomer-
ulus based on the method described by Okada et al [22] with a minor
modification. Grade 0 represented involvement of less than 10%, grade 1
between 10% and 30%, grade 2 between 30 and 60%, and grade 3
represented involvement exceeding 60%.
Tabular entries are Spearman’s rank correlations, with a probability of
c P , 0.01, d P , 0.05
Fig. 4. Immunohistochemistry for iNOS and CD68 on serial sections from a representative patient with IgAN (A and B; 3200), and double
immunostaining method demonstrating iNOS positive cells (blown color) and CD68 positive cells (blue color) on the same section from a representative
patient with LN (C and D; 3200). Although monocytes are occasionally observed in glomeruli (A, arrowheads), the staining pattern for iNOS (B,
arrows) is different from that of CD68. (C) Glomerular cells negative for CD68 stained iNOS (arrows). iNOS positive cell (arrowhead) in the glomeruli
also stained with anti-CD68 antibody. Macrophages stained blue but negative for iNOS were also observed (open arrows). (D) In some glomeruli, no
macrophages were present, while immunoreactive iNOS is present in the glomeruli (arrowheads).
™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™3
Fig. 5. Comparison between the expression of endothelial nitric oxide synthase (eNOS) and that of inducible nitric oxide synthase (iNOS; 3200). (A)
Endothelial expression of eNOS in the glomerulus (arrows) and peritubular capillaries. (B) A sequential section of (A). The staining pattern of iNOS
(arrowheads) is different from that of eNOS (A). Note that the expression of iNOS is observed in the area where eNOS is not expressed.
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iNOS was different from that for CD68. Double immunostaining
for iNOS and CD68 showed that glomerular cells negative for
CD68 were stained iNOS (Fig. 4C). In some glomeruli without
macrophage infiltration, immunoreactive iNOS was still detected
in the glomeruli (Fig. 4D). These results indicated that most of
iNOS-positive cells were glomerular resident cells and that a small
population of iNOS-positive cells was macrophages.
Comparison of the staining pattern of eNOS and iNOS on serial
sections showed that the staining pattern of eNOS was the reverse
of that of iNOS. The expression of iNOS was observed in the areas
where eNOS was not expressed (Fig. 5) and vice versa. Expression
of bNOS was not detected in normal and nephritic glomeruli.
The specificity of the anti-iNOS antibody was confirmed in
several experiments. First, preincubation of the antibody with
mouse iNOS abolished the reactivity of monoclonal antibody
(data not shown). Second, irrelevant monoclonal antibody of the
same subclass, nonspecific mouse IgG1 and IgG2 instead of the
primary antiserum, used as negative control, yielded no staining
(Fig. 2H). In addition, negative control with omission of the
primary antibody was also consistently negative (data not shown).
Moreover, samples immunostained with the polyclonal antibody
showed a staining pattern similar to that of the monoclonal
anti-iNOS antibody (data not shown).
None of the clinical parameters investigated in the present
study, that is, age, proteinuria, hematuria index and the level of
serum creatinine, correlated with the expression of eNOS and
iNOS.
DISCUSSION
The major finding of the present study was the detection of
specific immunostaining for eNOS and iNOS in the glomeruli of
human kidney. Cells positive for eNOS included glomerular
endothelial cells and the endothelium of afferent/efferent arte-
rioles and cortical vessels in normal and diseased glomeruli. iNOS
was expressed in mesangial cells, glomerular epithelial cells and
infiltrating cells in IgAN and LN. Interestingly, at each glomeru-
lus, a reciprocal expression pattern of eNOS and iNOS was
observed. Furthermore, in IgAN and LN, the expression of eNOS
correlated negatively with the degree of glomerular injury,
whereas the expression of iNOS correlated positively with the
degree of glomerular injury. To our knowledge, this is the first
presentation of the cellular distribution of eNOS and iNOS in
glomeruli of human renal biopsy specimens of patients with
various types of glomerulonephritis.
Our results of eNOS expression in normal kidney are in
agreement with those described in a previous immunohistochem-
ical study [16], and also established the expression of eNOS in
human nephritic glomeruli. Our findings are also in agreement
with the results of several in vitro studies [14, 28] demonstrating
eNOS expression in glomerular endothelial cells but not in
mesangial cells by Northern blot analysis. Thus, the present results
together with those of previous studies suggest that glomerular
endothelial cells participate in the NO pathway in normal and
diseased glomeruli through the synthesis of eNOS.
In terms of iNOS expression, it is important to search for
glomerular infiltrating monocytes as a possible source of NO,
since the macrophages are known to produce iNOS in certain
experimental model [18] and in vitro [17, 29]. In fact, Jansen et al
[18] reported that iNOS predominantly localized in macrophages
in glomeruli of rat models with immune complex glomerulone-
phritis. The difference in the findings of iNOS expression between
rats and human macrophages suggests that iNOS expression may
differ between species. This hypothesis is supported by Weinberg
et al [30], who reported that rodent macrophages appear to have
higher iNOS expression than human macrophages. In a human
study, Kashem and coworkers [31] reported that most of the iNOS
expressing cells appeared to be interstitial infiltrating cells, al-
though some weak focal staining for iNOS was found in the
glomerular cells in the renal tissue samples from patients with
IgAN. The reason for the discrepancy between the present results
and those of Kashem et al is unclear, but may be due to
differences in the methodologies employed, such as fixation of
tissue sections and the sensitivity of used avidin biotin complex
method. To differentiate infiltrating monocytes from iNOS-ex-
pressing cells, we performed two experiments. The first was
immunohistochemistry for iNOS on one section and for the
surface marker of monocytes (CD68) on serial sections. The other
experiment was the double staining for iNOS and surface marker
of macrophage. Based on the results of these experiments, it is
clear that while some macrophages express iNOS, the majority of
cells that contained iNOS were intrinsic glomerular cells, such as
mesangial cells and glomerular epithelial cells. Our results are in
agreement with some previous studies. Nicolson et al [32] showed
the synthesis of iNOS in cultured human mesangial cells stimu-
lated by cytokines. Wilkes and colleagues [33] demonstrated that
iNOS could be induced by cytokine stimulation in cultured
glomerular epithelial cells. In another study, Jansen et al [18]
showed weak focal immunostaining of iNOS in glomerular epi-
thelial cells in rat immune complex glomerulonephritis. Further-
more, to confirm the iNOS production by the glomerular resident
cells, two different antibodies were used and in situ hybridization
for iNOS mRNA was performed. Thus, our results indicated that
iNOS is induced in mesangial cells, and glomerular epithelial cells
and some infiltrating cells in the glomeruli of IgAN and LN.
Regarding the mechanism of iNOS production in the diseased
glomeruli, it is possible that certain cytokines are involved in the
induction of iNOS in the diseased glomeruli. In fact, the expres-
sion of IL-1b and TNF-a in the glomeruli of IgAN and LN has
already been reported [34, 35]. Moreover, in pathological states,
under the influence of various cytokines such as IL-1b and
TNF-a, NO is synthesized mainly by iNOS [2, 36]. The regulatory
mechanism of iNOS and eNOS should be clarified in further
studies.
In the present study, a negative correlation was observed
between eNOS expression and the degree of glomerular injury.
The decreased expression of eNOS in IgAN and LN with mod-
erate to severe lesion suggests that this alteration may contribute
to the progression of these renal diseases. Although the down-
regulatory mechanism of eNOS production in damaged glomeruli
was not clarified in this study, it is probable that glomerular
endothelial cells of injured glomeruli may reduce the expression
of eNOS during the progression of renal diseases. It is important
to determine whether reduced eNOS expression with enhanced
iNOS expression is the cause or result of renal injury in IgAN and
LN.
Although the exact role of NO in normal and diseased glomer-
uli is not fully understood, our results showed a reciprocal staining
pattern of eNOS and iNOS in each glomerulus. This finding, when
considered in conjunction with the different relationships between
each NOS and the degree of glomerular injury, allows us to
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speculate that the induction of iNOS may compensate the re-
duced production of eNOS or that eNOS and iNOS may have
different roles in the diseased glomeruli. Since the half-life of NO
is very short, the biological effects of NO depend on both the
concentration of NO at the site of action as well as the location of
production [2]. In fact, the amount of NO generated by eNOS is
small, in nmol quantities, whereas iNOS synthesizes NO in large
(mmol) quantities [2]. NO, which constitutively derived from
eNOS in the glomeruli, regulates glomerular microcirculation
under normal physiological conditions by modifying the tone of
the afferent arteriole and mesangial cells, and at the same time
maintains the antithrombogenic properties of the endothelium [2,
37]. The fact that the expression of eNOS decreased with the
progression of glomerular injury suggests that these physiological
effects of NO, produced by eNOS, diminish in severely damaged
glomeruli, leading to disturbances in microcirculation. In contrast,
high levels of NO, derived from iNOS, are cytotoxic or cytostatic
at least in vitro [36], and hamper cell function by reacting with iron
in numerous vital enzymes of the mitochondrial electron transport
chain and the citric acid cycle [2, 36]. In addition, NO may also
react with superoxide anion generated locally to form the reactive
peroxynitrite anion, which causes further tissue injury and lipid
peroxidation [2, 37]. On the other hand, NO may have a beneficial
effect in the nephritic glomeruli. Trachtman et al [38] reported
that NO inhibits the production of extracellular matrix protein by
mesangial cells. Increased production of extracellular matrix
protein in glomeruli, a process known to occur during the
progression of several forms of glomerulonephritis [39], may be
inhibit by locally generated NO. Based on these observations,
together with the present results, we suggest that NO derived
from eNOS and iNOS may be involved in the progression of
glomerulonephritis via complex pathways. Further studies are
warranted to understand the role of NO in the inflammatory
process in human glomerulonephritis.
In conclusion, our results indicate the presence of NO pathway
in the human diseased kidney. Our results also suggest that eNOS
and iNOS may participate in the process of glomerular injury
through different mechanisms.
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